屈光参差相关视觉功能与大脑神经机制关联研究

注册号:

Registration number:

ChiCTR2600125890 

最近更新日期:

Date of Last Refreshed on:

2026-06-01 15:43:45 

注册时间:

Date of Registration:

2026-06-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

屈光参差相关视觉功能与大脑神经机制关联研究

Public title:

Research on the Relationship between Visual Function in Anisometropia and Brain Neural Mechanisms

注册题目简写:

English Acronym:

研究课题的正式科学名称:

屈光参差相关视觉功能与大脑神经机制关联研究

Scientific title:

Research on the Relationship between Visual Function in Anisometropia and Brain Neural Mechanisms

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张妍 

研究负责人:

张妍 

Applicant:

Zhang Yan 

Study leader:

Zhang Yan 

申请注册联系人电话:

Applicant telephone:

+86 13604334101

研究负责人电话:

Study leader's
telephone:

+86 13604334101

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ahzhangyolanda@163.com

研究负责人电子邮件:

Study leader's E-mail:

ahzhangyolanda@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国上海市虹口区武进路85号

研究负责人通讯地址:

中国上海市虹口区武进路85号

Applicant address:

85 Wujin Road, Hongkou District, Shanghai, China

Study leader's address:

85 Wujin Road, Hongkou District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第一人民医院

Applicant's institution:

Shanghai First People's Hospital

研究负责人所在单位:

上海市第一人民医院

Affiliation of the Leader:

Shanghai General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

院伦快【2026】248号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第一人民医院人体试验伦理审查委员会

Name of the ethic committee:

Ethics Review Committee for Human Trials, Shanghai First People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-21 00:00:00

伦理委员会联系人:

耿雯倩

Contact Name of the ethic committee:

Geng Wenqian

伦理委员会联系地址:

中国上海市虹口区武进路85号

Contact Address of the ethic committee:

85 Wujin Road, Hongkou District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 36126254

伦理委员会联系人邮箱:

Contact email of the ethic committee:

13262983906@163.com

研究实施负责(组长)单位:

上海市第一人民医院

Primary sponsor:

Shanghai General Hospital

研究实施负责(组长)单位地址:

中国上海市虹口区武进路85号

Primary sponsor's address:

85 Wujin Road, Hongkou District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一人民医院

具体地址:

中国上海市虹口区武进路85号

Institution
hospital:

Shanghai General Hospital

Address:

85 Wujin Road, Hongkou District, Shanghai, China

经费或物资来源:

研究者发起临床研究基金

Source(s) of funding:

Researchers launch a clinical research fund

研究疾病:

屈光参差  

Target disease:

Anisometropia

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

主要研究目的 1. 明确长期屈光参差(≥1.00 D)是否导致成年患者大脑形成固定代偿性视觉网络及该网络的功能效率; 2. 探究近视手术对不同程度近视性屈光参差患者双眼视功能的改善差异,及手术诱导大脑视觉网络产生可塑性改变的机制。 次要研究目的: 1. 分析屈光参差患者眼动功能指标与大脑神经机制的关联; 2. 明确不同病程屈光参差对视觉功能及大脑网络的影响差异; 3. 验证术前立体视状态对术后功能恢复的预测价值。  

Objectives of Study:

Primary research objectives: 1. To clarify whether long-term anisometropia (>=1.00 D) leads to the formation of a fixed compensatory visual network in the adult brain and the functional efficiency of this network; 2. To explore the differences in binocular visual function improvement after myopia surgery in patients with varying degrees of myopic anisometropia, and the mechanism by which surgery induces plastic changes in the brain's visual network. Secondary research objectives: 1. To analyze the relationship between eye movement function indicators in anisometropic patients and brain neural mechanisms; 2. To clarify the differences in the effects of anisometropia of different disease courses on visual function and brain networks; 3. To verify the predictive value of preoperative stereopsis status for postoperative functional recovery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.年龄<18 岁; 2.圆锥角膜、疑似圆锥角膜或其他类型角膜扩张患者; 3.有显性斜视、眼外伤、眼睑缺损变形、屈光间质混浊、眼手术史、眼底疾病、眼部感染和活动性炎症等病变; 4.活动期自身免疫性及全身结缔组织疾病(如多发性硬化、系统性红斑狼疮等); 5.存在抑郁、焦虑等精神症状; 6.无法配合 MRI 或眼动仪检查; 7.模块 2 额外排除:角膜厚度不达标、活动性眼病等手术禁忌证;近两年屈光度数增长不稳定(每年增长>0.50 D);不愿 接受近视手术或无法遵循术后随访。

Exclusion criteria:

1.Age <18;
2.Patients with keratoconus, suspected keratoconus, or other types of corneal ectasia.
3.Presence of manifest strabismus, ocular trauma, eyelid defects or deformities, corneal or lens opacities, history of eye surgery, fundus diseases, eye infections, and active inflammation or other lesions.
4.Active period autoimmune and systemic connective tissue diseases (such as multiple sclerosis, systemic lupus erythematosus, etc.).
5.There are mental symptoms such as depression and anxiety.
6.Unable to cooperate with MRI or eye tracker examination.
7.Module 2 Additional Exclusions: Surgical contraindications such as insufficient corneal thickness or active eye disease; unstable refractive error growth in the past two years (annual increase >0.50 D); unwillingness to undergo myopia surgery or inability to comply with postoperative follow-up.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2029-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2028-12-31 00:00:00

干预措施:

Interventions:

组别:

屈光参差组

样本量:

50

Group:

Anisometropia group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

正常对照组

样本量:

50

Group:

Normal control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

正常对照组

样本量:

50

Group:

Normal control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

近视性屈光参差手术组

样本量:

50

Group:

Myopic anisometropia surgery group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

双眼视功能核心指标

指标类型:

主要指标

Outcome:

Core indicators of binocular vision function

Type:

Primary indicator

测量时间点:

模块 1 为基线期 1 次;模块 2 为术前、术后 1 月各 1 次

测量方法:

知觉眼位偏差:采用同视机检查和视知觉检查,测量双眼知觉眼位与客观眼位的偏差值(单位:棱镜度);立体视锐度:采用同视机检查和 Titmus Fly 立体图检查,记录立体视锐度阈值(单位:弧秒);双眼抑制程度:通过视知觉检查评估,记录抑制的程度(轻度、中度、重度)

Measure time point of outcome:

Module 1 is once during the baseline period; Module 2 is once preoperatively and once one month post

Measure method:

Perceptual ocular deviation: Measured using a synoptophore examination and visual perception test to determine the deviation between the perceptual ocular position and the objective ocular position (unit: prism diopters); Stereoscopic acuity: Measured using a synoptophore examination and the Titmus Fly stereogram test, recording the stereoscopic acuity threshold (unit: arcseconds); Degree of binocular suppression: Assessed through a visual perception test, recording the level of suppression (mil

指标中文名:

屈光与视力指标

指标类型:

次要指标

Outcome:

Refractive and Visual Acuity Indicators

Type:

Secondary indicator

测量时间点:

模块 1 为基线期 1 次;模块 2 为术前、术后 1 月各 1 次

测量方法:

裸眼视力 (LogMAR 视力 表) 、矫正视力(LogMAR 视力表)、双眼等效球镜度、柱镜度等,通过综合验光仪验光测量

Measure time point of outcome:

Module 1 is once during the baseline period; Module 2 is once preoperatively and once one month post

Measure method:

Unaided visual acuity (LogMAR visual acuity chart), corrected visual acuity (LogMAR visual acuity chart), binocular equivalent spherical power, cylindrical power, etc., measured using a comprehensive optometry instrument

指标中文名:

大脑代偿性视觉网络特征

指标类型:

主要指标

Outcome:

Characteristics of the brain's compensatory visual network

Type:

Primary indicator

测量时间点:

模块 1 为基线期 1 次;模块 2 为术前、术后 1 月各 1 次

测量方法:

采用 3.0T 核磁共振成像仪进行静息态 fMRI 和任务态 fMRI 扫描,由专业人员采用标准化数据处理软件进行分析,提取相关指标。

Measure time point of outcome:

Module 1 is once during the baseline period; Module 2 is once preoperatively and once one month post

Measure method:

Resting-state fMRI and task-based fMRI scans were performed using a 3.0T MRI machine, and the relevant indicators were extracted by professionals using standardized data processing software.

指标中文名:

眼动功能指标

指标类型:

次要指标

Outcome:

Oculomotor function indicators

Type:

Secondary indicator

测量时间点:

模块 1 为基线期 1 次;模块 2 为术前、术后 1 月各 1 次

测量方法:

采用眼动仪进行视觉搜索、多目标追踪等任务测试,由专业软件分析提取指标

Measure time point of outcome:

Module 1 is once during the baseline period; Module 2 is once preoperatively and once one month post

Measure method:

Use an eye tracker to conduct tasks such as visual search and multiple object tracking, with indicators analyzed and extracted by professional software.

指标中文名:

术后并发症发生情况

指标类型:

次要指标

Outcome:

Postoperative complications occurrence

Type:

Secondary indicator

测量时间点:

术后 1 月随访时评估

测量方法:

模块 2 中,记录术后 1 月内出现的各类手术相关并发症(如感染、角膜混浊、干眼等),包括并发症的类型、发生时间、严重程度及转归

Measure time point of outcome:

Assessment at 1-month postoperative follow-up

Measure method:

In Module 2, record various surgery-related complications that occur within 1 month postoperatively (such as infection, corneal opacity, dry eye, etc.), including the type of complication, time of occurrence, severity, and outcome.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用纸质病例报告表(CRF)收集数据,后续通过电子录入方式建立研究数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study uses paper case report forms (CRFs) to collect data, which will later be entered electronically to establish the research database.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-01 15:43:29